Eurofins Advinus Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eurofins Advinus Limited
Deal Watch: Takeda Continues Transaction Spree With Four More Deals
Takeda's recent deals include a license in Asian for Tesaro's PARP inhibitor Zejula. Meanwhile, Japanese rival Mitsubishi Tanabe is paying roughly $1bn to acquire Israel's NeuroDerm.
Takeda’s Planned Emerging Markets Deal: India Yay Or Nay?
Takeda tantalizingly disclosed during its third quarter results that it has set aside funds for an acquisition worth around $450m in an undisclosed emerging market. What are the likely targets?
INTERVIEW: Ex-Advinus CEO’s Bittersweet Journey
Life appears to have come full circle for Advinus Therapeutics' co-founder and former CEO and managing director, Dr. Rashmi Barbhaiya, who recently moved back to the US from India. It has been a bitter-sweet journey with peaks and troughs, although the man himself would rather see any lows as "lessons learned" that come with the territory.
New Takeda India Leadership Amid Realignment
Whether or not it's a rejig in the normal course of business isn't very clear but Japanese giant Takeda has "realigned" certain teams as it pursues plans to provide sustainable access to its medicines under a new leadership in India.
- Contract Research, Toxicology Testing-CRO
- Drug Discovery Tools
- Other Names / Subsidiaries
- Advinus Therapeutics Limited
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.